Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally.
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Immunovia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMMNOV's share price has been volatile over the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: IMMNOV underperformed the Swedish Medical Equipment industry which returned 15.8% over the past year.
Return vs Market: IMMNOV underperformed the Swedish Market which returned -6.4% over the past year.
Price Volatility Vs. Market
How volatile is Immunovia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StInsider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr500k Worth Of Shares
1 week ago | Simply Wall StCould The Immunovia AB (publ) (STO:IMMNOV) Ownership Structure Tell Us Something Useful?
1 month ago | Simply Wall StHere's What We Think About Immunovia AB (publ)'s (STO:IMMNOV) CEO Pay
Is Immunovia undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMMNOV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMMNOV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMMNOV is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: IMMNOV is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMMNOV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMMNOV is overvalued based on its PB Ratio (7x) compared to the SE Medical Equipment industry average (3.9x).
How is Immunovia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunovia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Immunovia's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Immunovia competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Immunovia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMMNOV is currently unprofitable.
Growing Profit Margin: IMMNOV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMMNOV is unprofitable, and losses have increased over the past 5 years at a rate of -53.8% per year.
Accelerating Growth: Unable to compare IMMNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMMNOV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).
Return on Equity
High ROE: IMMNOV has a negative Return on Equity (-32.02%), as it is currently unprofitable.
How is Immunovia's financial position?
Financial Position Analysis
Short Term Liabilities: IMMNOV's short term assets (SEK269.2M) exceed its short term liabilities (SEK28.6M).
Long Term Liabilities: IMMNOV's short term assets (SEK269.2M) exceed its long term liabilities (SEK33.1M).
Debt to Equity History and Analysis
Debt Level: IMMNOV is debt free.
Reducing Debt: IMMNOV has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMMNOV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMMNOV has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -40.8% each year.
What is Immunovia's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMMNOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IMMNOV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMMNOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMMNOV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMMNOV's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mats Grahn (57yo)
Mr. Mats Grahn has been Chief Executive Officer of Immunovia AB (publ) since 2013. Mr. Grahn served as the Vice President of Product Management of Protein Separations at GE Healthcare Ltd. He has more than ...
CEO Compensation Analysis
Compensation vs Market: Mats's total compensation ($USD363.46K) is about average for companies of similar size in the Swedish market ($USD468.25K).
Compensation vs Earnings: Mats's compensation has increased whilst the company is unprofitable.
|Chief Executive Officer||7.25yrs||kr3.68m||1.86% SEK46.7m|
|Chief Financial Officer||7.25yrs||no data||0.089% SEK2.2m|
|Operations Director||3.58yrs||no data||0.053% SEK1.3m|
|Chief Technology Officer||0.33yr||no data||no data|
|Chief Scientific Officer||7.25yrs||no data||0.26% SEK6.5m|
|Director of Investor Relations||no data||no data||no data|
|Chief Commercial Officer||5.25yrs||no data||0.16% SEK4.1m|
|Senior Vice President of Business Development||2.92yrs||no data||no data|
|Senior Vice President of Sales - North America||0.25yr||no data||no data|
|Vice President of Research & Development||6.25yrs||no data||0.17% SEK4.2m|
Experienced Management: IMMNOV's management team is seasoned and experienced (5.3 years average tenure).
|Chairman of the Board of Directors||13.25yrs||kr420.00k||8.7% SEK218.9m|
|Member of Scientific Advisory Board||3.83yrs||no data||no data|
|Member of Scientific Advisory Board||3.75yrs||no data||no data|
|Member of Advisory Board||4yrs||no data||no data|
|Member of Scientific Advisory Board||3.75yrs||no data||no data|
|Member of Scientific Advisory Board||2.75yrs||no data||no data|
Experienced Board: IMMNOV's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IMMNOV insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.
Immunovia AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Immunovia AB (publ)
- Ticker: IMMNOV
- Exchange: OM
- Founded: 2007
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr2.516b
- Shares outstanding: 19.65m
- Website: https://www.immunovia.com
Number of Employees
- Immunovia AB (publ)
- Medicon Village
- Scheelevägen 2
- Skåne County
- 223 81
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IMMNOV||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Dec 2015|
|0G8X||LSE (London Stock Exchange)||Yes||Share Capital||GB||SEK||Dec 2015|
|IMMV.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Dec 2015|
|IMMNOS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||SEK||Dec 2015|
Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. The company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/08 03:04|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.